[go: up one dir, main page]

WO2025067293A1 - Hélicase et utilisation associée - Google Patents

Hélicase et utilisation associée Download PDF

Info

Publication number
WO2025067293A1
WO2025067293A1 PCT/CN2024/121291 CN2024121291W WO2025067293A1 WO 2025067293 A1 WO2025067293 A1 WO 2025067293A1 CN 2024121291 W CN2024121291 W CN 2024121291W WO 2025067293 A1 WO2025067293 A1 WO 2025067293A1
Authority
WO
WIPO (PCT)
Prior art keywords
helicase
polynucleotide
target analyte
construct
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2024/121291
Other languages
English (en)
Chinese (zh)
Inventor
刘先宇
王玉博
鄢妍
刘凡贵
林建勋
兰静
李阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qitan Technology Ltd Beijing
Original Assignee
Qitan Technology Ltd Beijing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202311266570.0A external-priority patent/CN119709690A/zh
Priority claimed from CN202311261708.8A external-priority patent/CN119709689A/zh
Application filed by Qitan Technology Ltd Beijing filed Critical Qitan Technology Ltd Beijing
Publication of WO2025067293A1 publication Critical patent/WO2025067293A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing

Definitions

  • the invention belongs to the technical field of sequencing, and particularly relates to a modified helicase and an application thereof in characterizing a target analyte.
  • Nanopore sequencing technology also known as the fourth-generation sequencing technology, uses a nanopore that can provide an ion current channel to allow analytes such as single-stranded nucleic acid molecules to pass through the nanopore under the drive of electrophoresis.
  • analytes such as nucleic acids pass through the nanopore, the current of the nanopore will be reduced, and the gene sequencing technology can read the sequence information of the different signals generated in real time.
  • Helicases are a useful tool for controlling the movement of nucleic acid molecules during nanopore sequencing, but current helicases have some problems that need to be solved.
  • the helicase may fall off the nucleic acid molecule during sequencing, causing the nucleic acid molecule to be pulled through the pore at an uncontrolled speed and in an uncontrolled manner, so that the current signal of the analyte, such as a single nucleotide, is too short to be distinguished.
  • the prior art CN105899678A discloses a modified helicase. Specifically, at least one cysteine/non-natural amino acid is introduced into the tower/pin/1A domain of the helicase, thereby improving the continuous rate control ability of the helicase in nanopore sequencing.
  • the present application provides a new helicase modification method, which can also improve the continuous rate control ability of the helicase in nanopore sequencing, and has better effects in terms of sequencing stability and accuracy.
  • the present application provides a helicase
  • (c) comprising a polynucleotide binding domain, wherein the polynucleotide binding domain comprises an opening in at least one conformational state, through which a polynucleotide can be debound by the helicase, wherein the helicase forms an ectopic bond between two or more amino acids at the opening (forming the ectopic bond can prevent the polynucleotide from being debound by the helicase through the opening), and wherein the helicase retains its ability to control the movement of the target polynucleotide; or
  • (d) comprising a polynucleotide binding domain, wherein the polynucleotide binding domain comprises an opening in at least one conformational state, through which a polynucleotide can be debound from the helicase, wherein the helicase is modified so that it can form an ectopic bond between two or more amino acids at the opening (the formation of the ectopic bond can prevent the polynucleotide from being debound from the helicase through the opening), and wherein the helicase retains its ability to control the movement of the target polynucleotide.
  • the ectopic bond does not include an ectopic bond formed with the participation of cysteine, and the ectopic bond includes an ectopic bond formed with the participation of any natural amino acid except cysteine.
  • the arbitrary natural amino acid except cysteine is selected from the group consisting of the following amino acids: Ile, Val, Leu, Phe, Met, Ala, Gly, Thr, Ser, Trp, Tyr, Pro, His, Glu, Gln, Asp, Asn, Lys, Arg,
  • the ectopic bond comprises Lys-His, Lys-Ser, Lys-Thr, Lys-Tyr, Lys-Lys, Lys-Glu, Lys-Asp, Lys-Gln, Lys-Arg, Arg-Glu, Lys-Met, Arg-Asp, Arg-Arg, Tyr-Tyr, Tyr-Trp, Met-Met ectopic bond or a combination thereof;
  • the helicase consists of one or more monomers
  • the two amino acids forming the isopeptide bond are located in the same domain or in different domains.
  • the helicase is derived from a member of the natural or modified helicase family of the following group: Dda helicase, Pifl-like helicase, Upfl-like helicase, UvrD/Rep helicase, Ski-like helicase, Rad3/XPD helicase, NS3/NPH-II helicase, DEAD helicase, DEAHi RHA helicase, RecG-like helicase, REcQ-like helicase, T1R-like helicase, Swi/Snf-like helicase and Rig-I-like helicase, preferably Dda helicase, more preferably T4-Dda helicase;
  • the helicase is derived from a member of the natural or modified helicase family of the following groups: RecD helicase, Upfl helicase, PcrA helicase, Rep helicase, UvrD helicase, Hel308 helicase, Mtr4 helicase, XPD helicase, NS3 helicase, Mssl 16 Helicase, Prp43 helicase, RecG helicase, RecQ helicase, T1R helicase, RapA helicase and Hef helicase.
  • modified helicases such as helicases with amino acid mutations has a relatively complex production process and high cost.
  • unmodified natural helicases for covalent bonding such as ectopic bond bonding is simpler and easier for those skilled in the art, and can also improve the stability of controlling the movement of nucleic acid molecules through nanopores.
  • the unmodified natural helicase includes a polynucleotide binding domain and two RecA-like domains, and there is a connection between the natural amino acid residues located in different RecA-like domains, which has the ability to control the movement of polynucleotides; and compared with the absence of the connection, the presence of the connection enhances the ability of the modified helicase to control the movement of polynucleotides.
  • the natural amino acid residues that are connected have interactions and/or a spatial distance of less than 50 angstroms. The interaction includes electrostatic interaction, preferably, the interaction is generated after the helicase binds to the target polynucleotide.
  • the natural amino acid residues that are connected are naturally present in the helicase, preferably, the natural amino acid residues that are connected include glutamic acid, lysine, tyrosine, arginine, aspartic acid, cysteine, methionine, and tryptophan. In one embodiment, the natural amino acid residues that are connected are located around the polynucleotide binding domain.
  • the connection is a covalent connection, and preferably, the connection is an ectopic bond connection.
  • the covalent connection includes a connection formed by a chemical crosslinker, or a connection formed by an enzyme.
  • the chemical crosslinker includes EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride), EDC/NHS (N-hydroxysuccinimide), EDC/s-NHS (N-hydroxysuccinimide sulfonic acid sodium salt), chlorpyrifos oxon, HRP (horseradish peroxidase), laccase, or tyrosinase.
  • the helicase belongs to the SF1B (Superfamily 1B) subfamily helicase (The T4 phage SF1B helicase Dda is structurally optimized to perform DNA strand separation, Structure. 2012 Jul 3; 20 (7): 1189-200).
  • the helicase includes Dda helicase, RecD2 helicase, Pif1 helicase, or DNA helicase B. In one embodiment, the helicase is Dda helicase from T4 phage.
  • the natural amino acid residues present in the connection include E93, E94, K364, Y92, or Y363. In one embodiment, the natural amino acid residues present in the connection are selected from at least one of the following groups: E93 and K364; E94 and K364; or Y92 and Y363.
  • the natural or modified Dda helicase is from the Dda helicases in Table 1 and Table 2 disclosed in CN105899678A.
  • the natural or modified Pif1-like helicase is from the Pif1-like helicases in Table 1 and Table 2 disclosed in CN113930406A.
  • an ectopic bond is introduced between the natural amino acid residues in the 1A domain and the 2A domain of the helicase.
  • the ectopic bond comprises Lys-His, Lys-Ser, Lys-Thr, Lys-Tyr, Lys-Lys, Lys-Glu, Lys-Asp, Lys-Gln, Lys-Arg, Arg-Glu, Lys-Met, Arg-Asp, Arg-Arg, Tyr-Tyr, Tyr-Trp, Met-Met ectopic bond or a combination thereof.
  • the amino acid side chains are directly connected to form a covalent bond or are connected to form an ectopic bond by a connecting molecule.
  • the helicase is derived from a Dda helicase, preferably a T4-Dda helicase.
  • the helicase is derived from T4-Dda helicase, and the helicase comprises:
  • the helicase comprises any mutant of the 1A domain and/or any mutant of the 2A domain, as long as the helicase retains its ability to control the movement of the target analyte, preferably the target polynucleotide.
  • the target analyte is modified by methylation, oxidation, damage with one or more proteins or one or more markers, tags or spacers.
  • the target analyte is a target polynucleotide.
  • the present application provides a polypeptide comprising the 1A domain and the 2A domain that form an ectopic bond from the aforementioned helicase, and a polynucleotide binding domain, and excluding other domains of the helicase.
  • the present application provides a helicase, comprising the polypeptide, wherein the helicase has the ability to control the movement of a target analyte, preferably a target polynucleotide.
  • the present application provides a construct comprising a helicase or a polypeptide, and The target polynucleotide bound by its polynucleotide binding domain, wherein two or more amino acid residues on the surface of the helicase surrounding the polynucleotide binding domain are connected by an isopeptide bond, wherein the bound target polynucleotide is surrounded by the structure connected by the isopeptide bond.
  • the construct comprises an adapter, the target polynucleotide is connected to the adapter, and the construct has the ability to control the movement of the target polynucleotide.
  • the construct comprises two or more helicases.
  • the helicase may be any of the helicases described above, or a combination thereof.
  • the present application provides a polynucleotide comprising a sequence encoding the helicase, the polypeptide, the construct, or consisting of a sequence thereof.
  • the present application provides a vector comprising the polynucleotide operably linked to a promoter.
  • the present application provides a host cell, comprising the vector.
  • the present application provides a method for preparing the helicase, the polypeptide, or the construct, comprising expressing the polynucleotide, transfecting cells with the vector, or culturing the host cells.
  • the present application provides a method for controlling the movement of a target analyte, preferably a target polynucleotide, comprising contacting the target polynucleotide with the helicase or polypeptide, or the construct, and thereby controlling the movement of the target analyte, preferably the target polynucleotide.
  • the method is used to control the movement of a target analyte, preferably a target polynucleotide, through a pore.
  • the present application provides a method for characterizing a target analyte, preferably a target polynucleotide, comprising:
  • the target analyte is selected from one or more of polynucleotides, polypeptides, polysaccharides and lipids, preferably polynucleotides or polypeptides, polysaccharides and lipids linked to polynucleotides, more preferably single-stranded polynucleotides, double-stranded polynucleotides or partially double-stranded polynucleotides. Acid; or
  • the target analyte is a target polynucleotide, and the one or more characteristics are selected from (i) the length of the target polynucleotide, (ii) the identity of the target polynucleotide, (iii) the sequence of the target polynucleotide, (iv) the secondary structure of the target polynucleotide; and (v) whether the target polynucleotide is modified.
  • the target polynucleotide is modified by methylation, oxidation, damage with one or more proteins or one or more markers, tags or spacers.
  • one or more characteristics of the target analyte, preferably the target polynucleotide are measured by electrical measurement and/or optical measurement.
  • the electrical measurement is current measurement, voltage measurement, resistance measurement, capacitance measurement, inductance measurement, impedance measurement, tunnel measurement or field effect transistor measurement.
  • the method comprises:
  • the method further comprises the step of applying a voltage across the hole to form a complex between the hole and the helicase or construct.
  • the target analyte is a target polynucleotide, and at least part of the target polynucleotide is double-stranded.
  • the hole is a nanopore or a transmembrane hole, or the hole is selected from a biological hole, a solid-state hole, or a hole hybridized with a biological solid state.
  • the biological hole is derived from hemolysin, leukocidin, CsGG, Mycobacterium smegmatis porin A (MspA), porin B, porin C, porin D, outer membrane porin F, outer membrane porin G, outer membrane phospholipase A, Neisseria autotransporter, and WZA;
  • the solid-state hole is derived from a graphene nanopore, a MoS2 nanopore, a BN nanopore, or a PA63 nanopore.
  • the present application provides a method for forming a sensor for characterizing a target analyte, preferably a target polynucleotide, comprising forming a complex between (a) a hole and (b) the helicase or polypeptide, or the construct, and thereby forming a sensor for characterizing the target analyte, preferably a target polynucleotide.
  • the complex is formed by (a) contacting the pore and the helicase or construct in the presence of the target analyte, preferably the target polynucleotide, and (b) applying an electric potential across the pore.
  • the electric potential is a voltage potential or a chemical potential.
  • the complex is formed by covalently linking the pore to the helicase or construct.
  • the present application provides a sensor for characterizing a target analyte, preferably a target polynucleotide, comprising (a) a pore and (b) the helicase or polypeptide, or a complex between the constructs.
  • the present application provides the use of the helicase or polypeptide, or the construct in controlling the movement of a target analyte, preferably a target polynucleotide, through a pore.
  • the present application provides a kit for characterizing a target analyte, preferably a target polynucleotide, comprising (a) a pore and (b) the helicase or polypeptide, or the construct.
  • the kit further comprises a chip comprising an amphiphilic membrane.
  • the present application provides a device for characterizing a target analyte, preferably a target polynucleotide, comprising (a) a plurality of holes and (b) a plurality of the helicases or polypeptides, or the constructs.
  • the device comprises: a sensor device capable of supporting a plurality of pores and operable to use the pores and helicase or construct to characterize a target analyte, preferably a target polynucleotide; and at least one port for delivering a material for characterization.
  • the device comprises: a sensor device capable of supporting a plurality of pores and operable to use the pores and helicase or construct to characterize a target analyte, preferably a target polynucleotide; and at least one memory for storing materials for characterization; a fluidics system configured to controllably provide materials to the sensor device from the at least one memory; and one or more containers for receiving corresponding samples, the fluidics system being configured to selectively provide samples to the sensor device from one or more containers.
  • the present application provides a method for preparing the helicase, comprising:
  • step (b) the step of contacting the helicase with the polynucleotide is also included.
  • the ectopic bond comprises the use of H 2 O 2 , Hemin and H 2 O 2 , HRP enzyme and H 2 O 2 , transglutaminase, EDC, or Ru catalyzes the formation, more preferably, HRP enzyme and H 2 O 2 , or EDC.
  • the method further comprises (c) determining whether the obtained helicase is capable of controlling the movement of a target analyte, preferably a target polynucleotide.
  • the present application provides a method for preparing the construct, comprising connecting the helicase or polypeptide to a linker and thereby preparing the construct.
  • the method further comprises determining whether the obtained construct can control the movement of the target analyte, preferably the target polynucleotide.
  • the present application provides a group of two or more helicases attached to a target analyte, preferably a target polynucleotide, wherein at least one of the two or more helicases is the aforementioned helicase.
  • FIGS 1 to 4 show the enzyme cross-linking effect under the addition of different catalysts.
  • FIG. 5 shows the lock-enzyme cross-linking effect of different enzymes under HRP/H 2 O 2 catalysis according to one embodiment.
  • FIG. 6 shows the column purification elution process of a locked enzyme mutant based on Tyr-Tyr cross-linking according to one embodiment.
  • FIG. 7 shows a PAGE gel image of column purification elution of a nucleic acid-protein complex based on Tyr-Tyr cross-linking according to one embodiment.
  • FIG. 8 shows an on-machine test signal diagram of a nucleic acid-protein complex based on Tyr-Tyr cross-linking according to one embodiment.
  • FIG. 9 shows the gel electrophoresis of the nucleic acid-protein complex based on Tyr-Tyr cross-linking prepared in Example 2.1.
  • FIG. 10 shows the gel electrophoresis of the Lys-Glu cross-linked nucleic acid-protein complex prepared in Example 2.2.
  • FIG. 11 shows the column purification elution profile of the nucleic acid-protein complex purified in Example 2.3.
  • FIG. 12 shows the gel electrophoresis diagram of the nucleic acid-protein complex after elution in Example 2.3, wherein FT, E1, E2, and E3 represent nucleic acid-protein complexes corresponding to different main peaks in the elution process shown in FIG. 11 .
  • FIG. 13 shows the nucleic acid-protein complex after treatment with different reagents in Example 2.3 Gel electrophoresis diagram.
  • FIG. 14 shows the results of ATP consumption detection of nucleic acid-protein complexes in Example 2.4.
  • FIG. 15 shows the sequencing signal diagram of the nucleic acid-protein complex in Example 2.5, wherein FIG. A is a complete sequencing signal diagram of 10 kb, and FIG. B is a local amplification signal step diagram.
  • nucleotide includes two or more nucleotides
  • a helicase includes two or more helicases.
  • nucleotide sequence refers to a polymeric form of nucleotides (ribonucleotides or deoxyribonucleotides) of any length. The term refers only to the primary structure of the molecule. Thus, the term includes double-stranded and single-stranded DNA and RNA.
  • nucleic acid refers to a single-stranded or double-stranded covalently linked nucleotide sequence, wherein the 3' and 5' ends on each nucleotide are linked by a phosphodiester bond.
  • Nucleotides can be composed of deoxyribonucleotide bases or ribonucleotide bases.
  • Nucleic acids can include DNA and RNA, and can be synthesized and prepared in vitro or isolated from natural resources.
  • Nucleic acids can further include modified DNA or RNA, such as methylated DNA or RNA, or RNA modified after translation, such as 5'-capping with 7-methylguanosine, 3'-end processing, such as cleavage and polyadenylation, and splicing.
  • Nucleic acids can also include synthetic nucleic acids (XNA), such as hexitol nucleic acids (HNA), cyclohexene nucleic acids (CeNA), threose nucleic acids (TNA), glycerol nucleic acids (GNA), locked nucleic acids (LNA) and peptide nucleic acids (PNA).
  • HNA hexitol nucleic acids
  • CeNA cyclohexene nucleic acids
  • TAA threose nucleic acids
  • GNA glycerol nucleic acids
  • LNA locked nucleic acids
  • PNA peptide nucleic acids
  • nucleic acids or polynucleotides
  • the size of nucleic acids is usually expressed in terms of the number of base pairs (bp) for double-stranded polynucleotides, or in terms of the number of nucleotides (nt) in the case of single-stranded polynucleotides.
  • bp base pairs
  • nt nucleotides
  • One thousand bp or nt is equal to one kilobase pair (kb).
  • Polynucleotides less than about 40 nucleotides in length are generally referred to as "oligonucleotides" and may contain A primer in DNA manipulations, for example by the polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • a polynucleotide such as a nucleic acid
  • the polynucleotide or nucleic acid may comprise any combination of any nucleotides.
  • the nucleotides may be naturally occurring or artificially synthesized.
  • One or more nucleotides in the polynucleotide may be oxidized or methylated.
  • One or more nucleotides in the polynucleotide may be damaged.
  • the polynucleotide may comprise a pyrimidine dimer. Such dimers are generally associated with damage caused by ultraviolet light and are a major cause of melanoma of the skin.
  • One or more nucleotides in the polynucleotide may be modified, for example with a conventional marker or label.
  • the polynucleotide may comprise one or more nucleotides that are abasic (i.e., lack a nucleobase), or lack a nucleobase and a sugar (i.e., C3).
  • the nucleotides in the polynucleotide can be linked to each other in any manner.
  • the nucleotides are usually linked by their sugar and phosphate groups, as in nucleic acids.
  • the nucleotides can be linked by their nucleobases, as in pyrimidine dimers.
  • the polynucleotide may be single-stranded or double-stranded. At least a portion of the polynucleotide is preferably double-stranded.
  • the polynucleotide may be a nucleic acid, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
  • the polynucleotide may comprise an RNA chain hybridized to a DNA chain.
  • the polynucleotide may be any synthetic nucleic acid known in the prior art, such as a peptide nucleic acid (PNA), a glycerol nucleic acid (GNA), a threose nucleic acid (TNA), a locked nucleic acid (LNA) or other synthetic polymers having nucleotide side chains.
  • PNA peptide nucleic acid
  • GNA glycerol nucleic acid
  • TNA threose nucleic acid
  • LNA locked nucleic acid
  • the PNA backbone is composed of repeated N-(2-aminoethyl)-glycine units linked by peptide bonds.
  • the GNA backbone is composed of repeated ethylene glycol units linked by phosphodiester bonds.
  • the TNA backbone is composed of repeated threose groups linked together by phosphodiester bonds.
  • LNA is formed by the above-mentioned ribonucleic acid, with an additional bridging structure connecting the 2' oxygen and 4' carbon in the ribose moiety.
  • Bridged nucleic acids are modified RNA nucleotides. They can also be referred to as restricted or inaccessible RNA.
  • BNA monomers can contain 5-, 6- or even 7-membered bridges with a "fixed" C3'-endo sugar puckering. The bridges are synthetically introduced into the 2', 4'-position of the ribose to produce 2', 4'-BNA monomers.
  • the polynucleotide is most preferably ribonucleic acid (RNA) or deoxyribonucleic acid (DNA).
  • the polynucleotide can be of any length.
  • the length of the polynucleotide can be at least 10, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400 or at least 500 nucleotides or nucleotide pairs.
  • the length of the polynucleotide can be 1000 or more nucleotides or nucleotide pairs, 5000 or more nucleotides or nucleotide pairs or 100000 nucleotides or nucleotide pairs. or more nucleotides or nucleotide pairs.
  • any number of polynucleotides can be studied.
  • the method of the embodiment can involve characterizing 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 100 or more polynucleotides. If two or more polynucleotides are characterized, they can be different polynucleotides or the same polynucleotide.
  • the polynucleotide may be naturally occurring or artificially synthesized.
  • the method may be used to verify the sequence of the prepared oligonucleotide.
  • the method is typically performed in vitro.
  • protein protein
  • polypeptide and “peptide” are further used interchangeably herein to refer to polymers of amino acid residues as well as variants and synthetic analogs of amino acid residues. Thus, these terms apply to amino acid polymers in which one or more amino acid residues is a synthetic non-naturally occurring amino acid, such as a chemical analog of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
  • Polypeptides may also undergo maturation or post-translational modification processes, which may include, but are not limited to, glycosylation, proteolytic cleavage, lipidation, signal peptide cleavage, propeptide cleavage, phosphorylation, and the like.
  • Conservative substitution replaces amino acid with other amino acid with similar chemical structure, similar chemical property or similar side chain volume.
  • the amino acid introduced can have polarity, hydrophilicity, hydrophobicity, alkalinity, acidity, neutrality or charge similar to the amino acid they replace.
  • conservative substitution can introduce another aromatic or aliphatic amino acid to replace pre-existing aromatic or aliphatic amino acid.
  • Conservative amino acid changes are well known in the art and can be selected according to the properties of the 20 kinds of main amino acids defined in the following table 1. In the case where amino acid has similar polarity, this can also be determined with reference to the hydrophilicity scale of the amino acid side chain in Table 2.
  • Polynucleotide sequences can be derived and replicated using standard methods in the art. Suitable methods for site-directed mutagenesis are known in the art and include, for example, combinatorial chain reactions. Polynucleotides encoding the constructs of the embodiments can be prepared using techniques known in the art, such as those described in Sambrook, J. and Russell, D. (2001). Molecular Cloning A Laboratory Manual, 3rd Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  • the resulting polynucleotide sequence can then be incorporated into a recombinant replicable vector, such as a cloning vector.
  • the vector can be used to replicate the polynucleotide in a compatible host cell.
  • the polynucleotide sequence can be prepared by introducing the polynucleotide into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions that cause the vector to replicate. The vector can be recovered from the host cell.
  • the nanopore is the only channel for ions to pass through on both sides of the phospholipid membrane.
  • Speed-controlling proteins such as polynucleotide binding proteins (such as the helicase of the present application embodiment) act as motor proteins for nucleic acid molecules such as DNA, pulling the DNA chain so that it passes through the nanopore/protein pore/transmembrane pore in sequence with a step length of a single nucleotide.
  • the corresponding pore blocking signal will be recorded.
  • the present application provides a modified helicase, preferably a modified DNA-dependent ATP
  • the helicase of the modified helicase (Dda helicase), more preferably T4-Dda helicase.
  • the modification allows the modified helicase to remain bound to the analyte, preferably polynucleotide, for a longer period of time.
  • the modified helicase retains its ability to control the movement of the analyte, preferably polynucleotide. In other words, the modified helicase can still control the movement of the analyte, preferably polynucleotide.
  • the degree to which the helicase controls the movement of the analyte, preferably polynucleotide is generally changed by the modification, as described in detail below.
  • the helicase preferably the Dda helicase, more preferably the T4-Dda helicase is modified.
  • the modified helicase is usually modified compared to the corresponding wild-type helicase or natural helicase.
  • the helicase of the present application embodiment is artificial or non-natural.
  • the ability of a helicase to bind or not bind to a polynucleotide can be determined using any method known in the art. Suitable binding/not binding assays include, but are not limited to, native polyacrylamide gel electrophoresis (PAGE), fluorescence anisotropy, calorimetry, and surface plasmon resonance (SPR, such as Biacore TM ).
  • PAGE native polyacrylamide gel electrophoresis
  • SPR surface plasmon resonance
  • the ability of a helicase to unwind from a polynucleotide can be determined by measuring the time it takes for the helicase to control the movement of the polynucleotide. This can also be determined using any method known in the art.
  • the ability of a helicase to control the movement of a polynucleotide is typically analyzed in a nanopore system.
  • Modified helicase is a useful tool for controlling the movement of polynucleotides in the chain sequencing process.
  • the Dda helicase can control the movement of DNA with at least two active operation modes (when all necessary components for promoting movement are provided to the helicase, such as ATP and Mg 2+ ) and an inactive operation mode (when the necessary components for promoting movement are not provided to the helicase).
  • the Dda helicase moves along the DNA in the direction of 5'-3', but the orientation of the DNA in the nanopore (depending on which end of the DNA is captured) means that the enzyme can be used to move the DNA out of the nanopore against the direction of the applied field, or move the DNA into the nanopore along the direction of the applied field.
  • the helicase works against the direction of the field applied by the potential, and the spiral DNA is pulled out of the nanopore and pulled into the cis compartment.
  • the helicase works along the direction of the field applied by the potential, and the spiral DNA is pushed into the nanopore and enters the trans compartment.
  • the Dda helicase When the Dda helicase is not provided with the necessary components to facilitate movement, it can bind to the DNA and act as a brake to slow down the movement of the DNA as it is pulled into the pore by the applied field.
  • the inactive mode it does not matter whether the DNA is captured with the 3' or 5' end facing down, it is the applied field that pulls the DNA into the nanopore towards the trans side.
  • the pore is located in the helicase, while the enzyme acts as a brake.
  • the helicase's control over the movement of DNA can be described in a variety of ways, including ratcheting, sliding, and braking.
  • the problem in the sequencing process of polynucleotides is that the molecular motor controlling the movement of the polynucleotides may be released from the polynucleotides. This allows the polynucleotides to be rapidly pulled through the hole in an uncontrolled manner in the direction of the applied field.
  • the modified helicase of the present application embodiment does not unwind or release from the polynucleotides being sequenced. When the modified helicase controls the polynucleotides to move through the nanopore, the modified helicase can provide the increased polynucleotide read length.
  • the ability of the modified helicase of the present application embodiment to move the entire polynucleotide through the nanopore allows the polynucleotides to be evaluated to be characterized with the accuracy and speed improved than the known methods, such as its sequence. When the chain length increases and it is necessary to have a molecular motor with improved progress, this becomes more important.
  • the modified helicase of the present application embodiment is particularly effective for controlling the movement of 500 nucleotides or more nucleotides, for example 1000 nucleotides, 5000, 10000, 20000, 50000, 100000 or more nucleotides.
  • modified helicase in addition, the use of the modified helicase according to the embodiments of the present application means that lower helicase concentrations can be used.
  • the helicase of the modification of the present application embodiment is also a useful tool for isothermal polymerase chain reaction (PCR).
  • PCR isothermal polymerase chain reaction
  • the chain of double-stranded DNA is first separated by helicase and covered by single-stranded DNA (ssDNA)-binding protein.
  • ssDNA single-stranded DNA
  • two sequence-specific primers are usually hybridized to each edge of the DNA template.
  • the primer annealed to the template can be extended using DNA polymerase to prepare double-stranded DNA, and then two newly synthesized DNA products can be used as substrates by the helicase of the present application embodiment, enter the next round of reaction. Therefore, synchronous chain reaction occurs, causing the exponential amplification of the target sequence selected.
  • the modified helicase has the ability to control the movement of a polynucleotide.
  • the ability of the helicase to control the movement of a polynucleotide can be analyzed by any method known in the art.
  • the helicase can be contacted with a polynucleotide, and the position of the polynucleotide can be determined using standard methods.
  • the ability of the modified helicase to control the movement of a polynucleotide is analyzed in a nanopore system.
  • the modified helicases of the embodiments of the present application can be isolated, substantially isolated, purified or substantially purified. If the helicase is completely free of any other components such as lipids, polynucleotides, pore monomers or other proteins, the helicase is isolated or purified. If the helicase is mixed with a carrier or diluent that does not interfere with its intended use, the helicase is substantially isolated. For example, if the helicase contains less than 10%, less than 5%, less than 2% or less than 1% The helicase is substantially isolated or substantially purified if the helicase is present without other components of the pore such as lipids, polynucleotides, pore monomers or other proteins.
  • any helicase preferably Dda helicase, more preferably T4-Dda helicase can be modified according to the embodiments of the present application.
  • the Dda helicase is T4-Dda helicase.
  • Dda helicase usually contains the following five domains: 1A (RecA-type motor) domain, 2A (RecA-type motor) domain, tower domain, pin domain and hook domain (Xiaoping He et al., 2012, Structure; 20: 1189-1200). These domains can be identified using protein modeling, X-ray diffraction measurements of proteins in crystal form (Rupp B (2009). Biomolecular Crystallograph: Principles, Practice and Application to Structural Biology. New York: Gar 1and Science.), nuclear magnetic resonance (NMR) spectroscopy of protein solutions (Mark Rance; Cavanagh, John; Wayne J. Fairbrother; Arthur W. Hunt III; Skelton, N. Nicholas J. (2007).
  • the modified helicase is further modified to reduce its surface negative charge.
  • Surface residues can be identified in the same manner as the Dda domain described above.
  • Surface negative charge is typically surface negatively charged amino acids, such as aspartic acid (D) and glutamic acid (E).
  • the helicase is preferably modified to neutralize one or more surface negative charges by replacing one or more negatively charged amino acids with one or more positively charged amino acids, uncharged amino acids, non-polar amino acids and/or aromatic amino acids, or by introducing one or more positively charged amino acids, preferably adjacent to one or more negatively charged amino acids.
  • Suitable positively charged amino acids include, but are not limited to, histidine (H), lysine (K) and arginine (R). Uncharged amino acids have no net charge.
  • Suitable uncharged amino acids include, but are not limited to, cysteine (C), serine (S), threonine (T), methionine (M), asparagine (N) and glutamine (Q).
  • Non-polar amino acids have non-polar side chains.
  • Suitable non-polar amino acids include, but are not limited to, glycine (G), alanine (A), proline (P), isoleucine (I), leucine (L) and valine (V).
  • Aromatic amino acids have Aromatic Side Chains.
  • Suitable aromatic amino acids include, but are not limited to, histidine (H), phenylalanine (F), tryptophan (W) and tyrosine (Y).
  • Preferred substitutions include, but are not limited to, R for E, K for E, N for E, K for D, and R for D.
  • the embodiment provides a modified helicase, forming an ectopic bond between the 1A domain and the 2A domain of the helicase.
  • the operation of introducing non-natural amino acids is relatively cumbersome and costly, while the introduction of disulfide bonds is less stable and easily opened by reducing agents.
  • the introduction of natural side chains into the 1A domain and the 2A domain can form ectopic bonds.
  • Heteropeptide bonds are a type of covalent bond formed by the reaction of amino acid R chains in addition to backbone peptide bonds in proteins. Heteropeptide bonds can be formed within protein molecules or between protein molecules in the natural environment. Generally, isopeptide bonds formed within molecules help proteins respond to environmental stress and improve protein stability (DOI:10.1016/j.tibs.2010.09.007), while isopeptide bonds formed between protein molecules can be used in the food industry (doi:10.1007/s12223-013-0287-x) or in protein-protein interaction research. The formation of heteropeptide bonds can be divided into three ways: self-catalytic formation within proteins, enzymatic catalysis, and chemical catalysis. The following lists specific examples of these three types of formation methods.
  • Lys-Asp ectopic bonds also known as isopeptide bonds
  • CnaA/CnaB proteins common examples include CnaA/CnaB proteins. Therefore, by forming a hydrophobic environment and introducing specific reactive and catalytic amino acids, ectopic bonds can be spontaneously formed within proteins.
  • This type of ectopic bond can also be transformed into a polypeptide ligase/bisubstrate form, that is, the protein that can spontaneously form an isopeptide bond is divided into a catalytic protein and two polypeptides with side chains that can react to form an ectopic bond.
  • the polypeptides with side chains that can react to form an ectopic bond can be integrated into the site where a covalent bond needs to be formed in the form of a recombinant protein.
  • Examples include the SpyTag/KTag ectopic bond connection catalyzed by SpyLiagse based on CnaB modification (doi/10.1073/pnas.ss11113) and the SnoopTagJr/DogTag connection catalyzed by SnoopLigase based on RrgA C-terminal domain modification.
  • Enzymatic catalysis This type of method involves many reactions, such as peroxidase (HRP, The dityrosine or trityrosine covalent bonds formed by myeloperoxidase Tyrosinas, laccase, etc. (DOI: 10.1021/acsbiomaterials.6b00454), this cross-linking reaction can also be catalyzed by G4-hemin nuclease (DOI: 10.1002/chem.201101941); Lys-Gln ectopic bonds (also known as isopeptide bonds https://doi.org/10.1016/j.ijbiomac.2017.10.115) catalyzed by transglutaminase; Lys-Lys cross-links catalyzed by lysyloxidases (doi: 10.1021/Bm1010195).
  • HRP peroxidase
  • Chemical cross-linking method produces many ectopic bonds, such as the isopeptide bonds formed between the side chains of D/E acidic amino acids and K/R basic amino acids catalyzed by EDC/NHS/S-NHS, Tyr-Tyr covalent cross-linking catalyzed by H 2 O 2 /Hemin, ruthenium, and cross-linking between D/E and D/E mediated by diazo-containing cross-linkers (doi.org/10.1021/acs.analchem.7b03789).
  • ectopic bonds in which non-Cys participate include, but are not limited to, Lys-His, Lys-Ser, Lys-Thr, Lys-Tyr, Lys-Lys, Lys-Glu, Lys-Asp, Lys-Gln, Lys-Arg, Arg-Glu, Lys-Met, Arg-Asp, Arg-Arg, Tyr-Tyr, Tyr-Trp, Met-Met, and these amino acid side chains can directly form covalent bonds or can be connected through other linker molecules.
  • the ectopic bond can be Tyr-Tyr, Lys-Lys, Gln-Lys, Glu-Lys, etc.
  • an ectopic bond is formed between the 1A domain and the 2A domain of a helicase, preferably a Dda helicase, more preferably a T4-Dda helicase.
  • an ectopic bond is introduced between the natural amino acid residues of the 1A domain and the 2A domain of the helicase.
  • the ectopic bond comprises a Tyr-Tyr ectopic bond, a Lys-Lys ectopic bond, a Gln-Lys ectopic bond, a Glu-Lys ectopic bond or a combination thereof.
  • the helicase is derived from a T4-Dda helicase, and the helicase comprises: (1) a Tyr-Tyr ectopic bond formed between x1 and x2; (2) a Lys-Gln ectopic bond formed between x3 and x4; (3) a Tyr-Lys ectopic bond formed between x1 and x3; (4) a Tyr-Gln ectopic bond formed between x1 and x4; (5) a Tyr-Lys ectopic bond formed between x2 and x3; (6) a Tyr-Gln ectopic bond formed between x2 and x4; (7) a Lys-Glu ectopic bond formed between x3 and x5; or (8) any combination thereof.
  • the helicase is further modified to reduce its surface negative charge. In one embodiment, the helicase is further modified to reduce its surface negative charge by replacing one or more negatively charged amino acids with one or more positively charged amino acids, uncharged amino acids, non-polar amino acids and/or aromatic amino acids, or by introducing one or more negatively charged amino acids near one or more negatively charged amino acids. positively charged amino acids to neutralize one or more surface negative charges.
  • the helicase includes any mutant of the 1A domain or any mutant of the 2A domain, as long as the helicase retains its ability to control the movement of the target analyte, preferably the target polynucleotide.
  • the target analyte comprises a polynucleotide, a polypeptide, a polysaccharide, or a lipid, preferably a polynucleotide.
  • the polynucleotide comprises DNA and/or RNA.
  • a variant of a helicase such as a variant of a Dda helicase, is an enzyme having an amino acid sequence that is varied from the amino acid sequence of a wild-type helicase and retains polynucleotide binding activity.
  • Polynucleotide binding activity can be determined using methods known in the art. Suitable methods include, but are not limited to, fluorescence anisotropy, tryptophan fluorescence, and electrophoretic mobility shift assay (EMSA).
  • the variant retains helicase activity. This can be determined using a variety of methods. For example, the ability of the variant to translocate along a polynucleotide can be determined using electrophysiological methods, fluorescence analysis, or ATP hydrolysis.
  • the variants may include modifications that facilitate processing of the helicase encoding polynucleotide or facilitate activity of the polynucleotide at high salt concentrations and/or room temperature.
  • Embodiment provides the fragment of helicase, for example the fragment of Dda helicase (more preferably T4-Dda helicase), it can be used to prepare the helicase of the embodiment of the present application.
  • polypeptide comprises 1A domain and 2A domain from Dda helicase (preferably T4-Dda helicase) and does not comprise any other domain from Dda helicase, wherein ectopic bond is formed between 1A domain and 2A domain.
  • Described polypeptide can comprise the variant of arbitrarily 1A domain and 2A domain defined above.
  • the present application embodiment also provides a construct comprising a Dda helicase or a modified Dda helicase (preferably a modified T4-Dda helicase) of the present application embodiment and an adapter, wherein the helicase is connected to the adapter and the construct has the ability to control the movement of a target analyte, preferably a target polynucleotide.
  • the construct is artificial or non-natural.
  • the construct is a useful tool for controlling the movement of target analytes, preferably target polynucleotides, during strand sequencing.
  • the helicase is uncoupled from the target analyte, preferably target polynucleotide, being sequenced.
  • the construct may even provide longer read lengths of the target analyte, preferably target polynucleotide.
  • Targeting constructs can also be designed to bind to specific polynucleotide sequences.
  • the adaptor can bind to a specific polynucleotide sequence and thereby target the helicase portion of the construct to that specific sequence.
  • the construct has the ability to control the movement of a target analyte, preferably a target polynucleotide. This can be determined as described above.
  • the constructs of the present application embodiments can be separated, substantially separated, purified or substantially purified. If the construct is completely free of any other components such as lipids, polynucleotides or pore monomers, the construct is separated or purified. If the construct is mixed with a carrier or diluent that does not interfere with its intended use, the construct is substantially separated. For example, if the construct exists in the form of containing less than 10%, less than 5%, less than 2% or less than 1% of other components such as lipids, polynucleotides or pore monomers, the construct is substantially separated or substantially purified.
  • the Dda helicase can be any Dda helicase.
  • Preferred Dda helicases include, but are not limited to, T4-Dda helicase and variants thereof. The variants are as described above.
  • the helicase is preferably a modified Dda helicase, more preferably a T-Dda helicase.
  • the helicase of any embodiment may be present in the construct of the embodiment of the present application.
  • the helicase is preferably covalently linked to the adapter.
  • the helicase can be linked to the adapter at more than one site, such as two or a single site.
  • the helicase can be linked to the adapter using any method known in the art.
  • the helicase and the adapter can be prepared separately and then connected together.
  • the two components can be connected in any configuration. For example, they can be connected by their terminal (i.e., amino terminal or carboxyl terminal) amino acids. Suitable configurations include, but are not limited to, the amino terminal of the adapter is connected to the carboxyl terminal of the helicase and vice versa.
  • the two components can be connected by the amino acids in their sequences.
  • the polynucleotide binding portion can be connected to one or more amino acids in the annular region of the helicase. In a preferred embodiment, the terminal amino acid of the polynucleotide binding portion is connected to one or more amino acids in the annular region of the helicase.
  • the helicase is chemically linked to the adaptor.
  • the adaptor For example, connected by one or more connector molecules.
  • Each connector can have two or more functional ends, such as two, three or four functional ends. Suitable terminal configurations in connectors are known in the art.
  • the helicase is fused to the adapter gene. If the entire construct is expressed from a single polynucleotide sequence, the helicase is fused to the adapter gene.
  • the coding sequences of the helicase and the multi-adapter can be combined in any manner to form a single polynucleotide sequence encoding the construct.
  • the helicase and the adapter can be genetically fused in any configuration.
  • the helicase and the polynucleotide binding portion can be fused through their terminal amino acids.
  • the amino terminus of the polynucleotide binding portion can be fused with the carboxyl terminus of the helicase and vice versa.
  • the amino acid sequence of the polynucleotide binding portion is preferably added to the amino acid sequence of the helicase in frame.
  • the polynucleotide binding portion is preferably inserted into the sequence of the helicase.
  • the helicase and the distribution are usually connected at two sites, i.e., by the amino terminus and carboxyl terminus of the adapter.
  • the adapter is inserted into the sequence of the helicase, the amino terminus and carboxyl terminus of the preferred part are very close and are each connected to adjacent amino acids in the sequence of the helicase or its variant.
  • the adapter is inserted into the annular region of the helicase.
  • the helicase can be directly connected to the adapter.
  • the helicase is preferably connected to the part using one or more, such as two or three, connectors as described above.
  • One or more connectors can be designed to limit the mobility of the part.
  • the helicase and/or the adapter can be modified to facilitate the connection of one or more connectors as described above.
  • the shearable connector can be used to help separate the construct from the non-connected components and can be used to further control the synthesis reaction.
  • a heterogeneous-bifunctional connector can react with a helicase, but not with the partial reaction. If the free end of the connector is used to connect the helicase protein to a surface, the unreacted helicase from the first reaction can be removed from the mixture. Subsequently, the connector can be sheared to expose the group reacted with the adapter.
  • the reaction conditions with the helicase can be optimized first, and then the reaction conditions with the adapter can be optimized after the connector is sheared off. The second reaction can be carried out more directly towards the correct site for reacting with the adapter, because the connector is confined to the region where it has been connected.
  • the The enzyme may be covalently linked to the bifunctional cross-linker.
  • the moiety may be covalently linked to the bifunctional cross-linker before the bifunctional cross-linker/moiety complex is linked to the helicase.
  • the helicase and the adaptor may be covalently linked to the chemical cross-linker simultaneously.
  • Cross-linking of the helicase or moiety itself can be prevented by maintaining a large excess of the connector concentration to the helicase and/or moiety.
  • a "lock and key" setup can be used where two connectors are used. Only one end of each connector can be reacted together to form a longer connector, and the other ends of the connectors are reacted separately with different parts of the construct (i.e., the helicase or moiety).
  • the attachment site is selected so that, when the construct is contacted with the polynucleotide, both the helicase and the adaptor can bind to the polynucleotide and control its movement.
  • the helicase and the adapter can be used to promote connection.
  • complementary polynucleotides can be used to combine the helicase and the adapter together when the helicase and the adapter are hybridized.
  • the helicase can be bound to a polynucleotide and the adapter can be bound to a complementary polynucleotide.
  • the two polynucleotides can then hybridize with each other. This allows the helicase to be in close contact with the adapter, so that the ligation reaction is more effectively carried out. This is particularly conducive to connecting two or more helicases in the correct direction to control the movement of the target polynucleotide.
  • Tags can be added to the construct to facilitate purification of the construct. These tags can then be chemically or enzymatically cleaved if they need to be removed. Fluorophores or chromophores can also be included, which can also be cleaved.
  • a simple way to purify the construct is to include different purification tags on each protein (i.e. the helicase and the polynucleotide binding portion), such as a 6His tag and a Strep tag. This method is particularly useful if the two proteins are different from each other. Using two tags only allows substances with both tags to be easily purified. If the two proteins do not have two different tags, other methods can be used.
  • the constructs can be purified from unreacted proteins based on different DNA processivity properties.
  • the constructs can be purified from unreacted proteins based on: increased affinity for the target analyte, preferably the target polynucleotide, reduced likelihood of dissociation from the analyte, preferably the polynucleotide after binding, and/or increased read length of the analyte, preferably the polynucleotide when it controls translocation of the analyte, preferably the polynucleotide through the nanopore.
  • Targeting constructs can also be designed to bind to specific polynucleotide sequences.
  • the adapter can bind to a specific polynucleotide sequence and thereby target the helicase portion of the construct. to that specific sequence.
  • the construct includes an adapter.
  • the adapter is a polypeptide that can bind to an analyte, preferably a polynucleotide.
  • the adapter preferably can specifically bind to a defined polynucleotide sequence.
  • the multi-adapter binds to a specific polynucleotide sequence, while binding to a different sequence cannot be detected. The portion that binds to a specific sequence can be used to design a construct that targets the sequence.
  • the adapter has at least one property of interacting with or modifying a polynucleotide.
  • the adapter can modify the polynucleotide by shearing it to form a single nucleotide or a shorter nucleotide chain such as two or three nucleotides.
  • the adapter can modify the polynucleotide by positioning it or moving it to a specific position, i.e. controlling its movement.
  • the adapter is derived from a polynucleotide binding enzyme.
  • a polynucleotide binding enzyme is a polypeptide that can bind to a polynucleotide and can interact with the polynucleotide and modify at least one of its properties.
  • the enzyme can modify the polynucleotide by shearing the polynucleotide into a single nucleotide or a shorter nucleotide chain, such as a dinucleotide or a trinucleotide.
  • the enzyme can modify the polynucleotide by directing or moving it to a specific position.
  • the polynucleotide binding portion does not need to show enzymatic activity, as long as it can bind to the polynucleotide and control its movement.
  • the portion can be derived from an enzyme that has been modified to remove its enzymatic activity or can be used under conditions that prevent it from acting as an enzyme.
  • the adaptor is derived from a nucleolytic enzyme.
  • preferred enzymes are exonucleases, polymerases, helicases and topoisomerases, such as gyrase.
  • the adapter is connected to the helicase and the target analyte (preferably the target polynucleotide).
  • the adapter is a nucleic acid.
  • the adapter is a polynucleotide.
  • the adapter includes a double-stranded nucleic acid region that can connect to other double-stranded nucleic acids, such as target polynucleotides.
  • the adapter is a Y-shaped adapter.
  • the adapter is composed of three DNA chains.
  • the adapter includes a spacer, preferably the spacer is inserted in the adapter, or the spacer is located at the 5' end or 3' end of one chain.
  • the adapter is a polynucleotide comprising a spacer. In one embodiment, the adapter is a Y-shaped polynucleotide comprising a spacer. In one embodiment, the adapter is a polynucleotide, polypeptide, polysaccharide or lipid containing a spacer.
  • the helicase can be arrested on the spacer of the adapter. By connecting the helicase and the adapter The polynucleotide (or polypeptide or polysaccharide or lipid) on the adapter contacts the transmembrane pore and applies an electric potential, which can move the stalled helicase through the spacer on the adapter.
  • the polynucleotide (or polypeptide or polysaccharide or lipid) of the adapter moves through the transmembrane pore along the electric potential, and the force generated moves the helicase through the spacer.
  • a plurality of adapters are included.
  • the adapter is part of the target analyte, or is not part of the target analyte.
  • other adapters may be interspersed in the target analyte (preferably the target polynucleotide).
  • the present application embodiment provides a polynucleotide containing a sequence encoding a helicase of the present application embodiment, a polypeptide of the present application embodiment, or a construct of the present application embodiment.
  • the polynucleotide may contain such a sequence.
  • the polynucleotide may be any polynucleotide discussed above.
  • Polynucleotide sequences can be isolated and replicated using standard methods in the art. Chromosomal DNA can be extracted from organisms that produce helicases, such as Methanococcus burtonii and/or organisms that produce SSB, such as Escherichia coli. PCR with specific primers can be used to amplify the gene coding sequence of interest. The amplified sequence can then be inserted into a recombinant replication vector such as a cloning vector. The vector can be used to replicate the polynucleotide in a compatible host cell.
  • a polynucleotide sequence can be prepared by introducing a polynucleotide encoding a sequence of interest into a replicable vector, including introducing the vector into a compatible host cell, and growing the host cell under conditions that cause the vector to replicate.
  • the vector can be recovered from the host cell.
  • Suitable host cells for cloning polynucleotides are known in the art and are described in more detail below.
  • the polynucleotide sequence can be cloned into a suitable expression vector.
  • the polynucleotide sequence is usually operably linked to a control sequence that can provide expression of the coding sequence by a host cell.
  • the expression vector can be used to express a construct.
  • operably linked refers to a juxtaposition wherein the various components described are in a relationship permitting them to function in their intended manner.
  • a control sequence "operably linked" to a coding sequence is linked under conditions compatible with the control sequences in a manner that achieves expression of the coding sequence. Multiple copies of the same or different polynucleotides may be introduced into a vector.
  • the expression vector can then be introduced into a suitable host cell.
  • the polynucleotide sequence encoding the construct can be introduced into an expression vector, including introducing the vector into The construct is prepared by introducing the polynucleotide sequence into a compatible bacterial host cell and growing the host cell under conditions that result in expression of the polynucleotide sequence.
  • the vector can be, for example, a plasmid, virus or phage vector with a replication origin, optionally a promoter for expressing the polynucleotide sequence, and optionally a regulatory factor for the promoter.
  • the vector can contain one or more selectable marker genes, such as an ampicillin resistance gene. Promoters and other expression control signals compatible with the host cell (for which the expression vector is designed) can be selected. T7, trc, lac, ara or k promoters are usually used.
  • the host cell typically expresses the construct at a high level.
  • a host cell compatible with the expression vector used to transform the host cell is selected for polynucleotide sequence transformation.
  • the host cell is typically bacterial and preferably E. coli. Any cell with a ⁇ DE3 lysogen, such as Rosetta2(DE3)pLys, C41(DE3), BL21(DE3), JM109(DE3), B834(DE3), TUNER, Origami and Origami B, can express vectors containing a T7 promoter.
  • the present application embodiment also provides the group (series) of two or more helicases that have been connected (or combined) polynucleotide, wherein at least one of the two or more helicases is the helicase of the present application embodiment, preferably Dda helicase, more preferably T4-Dda helicase.
  • the group can include any number of helicases, such as 2,3,4,5,6,7,8,9,10 or more helicases. Any number of helicases can be the helicase of the present application embodiment, preferably Dda helicase, more preferably T4-Dda helicase.All of two or more helicases are preferably the helicase of the present application embodiment, preferably Dda helicase, more preferably T4-Dda helicase.
  • One or more helicases of the present application embodiment, preferably Dda helicase, more preferably T4-Dda helicase can be any helicase discussed above, preferably Dda heli
  • the two or more helicases can be the same or different helicases.
  • the group includes two or more helicases of the present application embodiments, preferably Dda helicases, more preferably T4-Dda helicases
  • the helicases of the present application embodiments, preferably Dda helicases, more preferably T4-Dda helicases can be the same or different.
  • the group may include any number and combination of helicases of the embodiments of the present application, preferably Dda helicases, more preferably T4-Dda helicases.
  • the group of two or more helicases preferably includes at least two helicases of the embodiments of the present application, preferably Dda helicases, more preferably T4-Dda helicase.
  • the group may include two or more helicases, preferably Dda helicases, more preferably T4-Dda helicases.
  • Each helicase, preferably Dda helicase, more preferably T4-Dda helicase comprises the modification described above, including that the 1A domain and the 2A domain form an ectopic bond.
  • the group may include one or more helicases that are not part of the embodiments of the present application.
  • the one or more helicases may be or are derived from Hel308 helicases, RecD helicases, such as Tral helicases or TrwC helicases, XPD helicases or Dda helicases.
  • the one or more helicases may be any helicase in a helicase, modified helicase or helicase construct disclosed in the following international applications: International Application No. PCT/GB2012/052579 (Publication No.
  • WO 2013/057495 PCT/GB2012/053274 (Publication No. WO 2013/098562); PCT/GB2012/053273 (Publication No. WO 2013/098564); 13/098561); PCT/GB2013/051925 (published as WO 2014/013260); PCT/GB2013/051924 (published as WO 2014/013259) and PCT/GB2013/051928 (published as WO 2014/013262); and UK application No. 1318464.3 filed on 18 October 2013.
  • the one or more helicases are preferably modified to reduce the size of the opening in the polynucleotide binding domain through which the polynucleotide can be released from the helicase in at least one conformational state. This is disclosed in WO 2014/013260.
  • the two or more helicases in the group may be separated from each other.
  • the two or more helicases in the group may be bound together by the transmembrane pore as the polynucleotide moves through the pore.
  • the two or more helicases in the group may contact each other.
  • the two or more helicases are not linked to each other except by the polynucleotide.
  • the two or more helicases are preferably not covalently linked to each other.
  • the two or more helicases can be connected to each other or covalently connected to each other.
  • the helicases can be connected in any order and using any method.
  • a group of connected helicases can be called a team.
  • the present invention provides a method for controlling the movement of a target analyte, preferably a target polynucleotide.
  • the method comprises allowing the target analyte, preferably a target polynucleotide, to move with a helicase of the embodiment, preferably a Dda helicase, more preferably a T4-Dda helicase or a construct of the present invention.
  • the method is preferably carried out under a potential applied across the pore.
  • the applied potential generally results in the formation of a complex between the pore and the helicase or construct.
  • the applied potential may be a voltage potential.
  • the applied potential may be a chemical potential.
  • An example of this is the use of a salt gradient across the amphiphilic layer. Salt gradients are disclosed in Holden et al., J Am Chem Soc. 2007 Jul 11; 129(27): 8650-5.
  • the present application embodiment also provides a method for characterizing the preferred target polynucleotide of target analyte.
  • the method includes (a) contacting the preferred target polynucleotide of target analyte with the helicase of hole and embodiment, preferably Dda helicase, more preferably T4-Dda helicase or the construct of the present application embodiment, so that the helicase or construct control the preferred target polynucleotide of target analyte through the movement of the hole.
  • the method also includes (b) as the preferred polynucleotide of target analyte moves relative to the hole, obtaining one or more measured values, wherein the measured value represents one or more features of the preferred target nucleotide of the target analyte, and thus characterizing the preferred target polynucleotide of target analyte.
  • the helicase can be any helicase as described above for the constructs of the embodiments of the present application, including the modified helicases of the embodiments of the present application, preferably Dda helicases, more preferably T4-Dda helicases, and helicases not modified according to the embodiments of the present application, preferably Dda helicases, more preferably T4-Dda helicases.
  • helicases of the present application embodiment can use any number of helicases of the present application embodiment in these methods, preferably Dda helicase, more preferably T4-Dda helicase.
  • 1,2,3,4,5,6,7,8,9,10 or more helicases can be used.
  • two or more helicases of the present application embodiment preferably Dda helicase, more preferably T4-Dda helicase, they can be identical or different.Suitable number and combination are as described in the group for the present application embodiment above.They can be equally applied to the method for the present application embodiment.
  • two or more helicases may be linked to each other.
  • the two or more helicases may be covalently linked to each other.
  • the helicases may be linked in any order and using any method.
  • two or more helicases are used, they are preferably not linked to each other except by the polynucleotide.
  • the two or more helicases are more preferably not covalently linked to each other.
  • Steps (a) and (b) are preferably performed under conditions where a potential is applied across the pore as described above.
  • the current passing through the pore is used to determine the amount of polynucleotide that moves relative to the pore.
  • the sequence of the target polynucleotide is determined by the DNA sequencing. This is called strand sequencing.
  • the method of the embodiment of the present application is used to characterize the target analyte, preferably the target polynucleotide.
  • the polynucleotide is as defined above.
  • the whole or only part of the target polynucleotide can be characterized using this method.
  • the target polynucleotide can be any length.
  • the polynucleotide can be at least 10, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400 or at least 500 nucleotide pairs in length.
  • the polynucleotide can be 1000 or more nucleotide pairs, 5000 or more nucleotide pairs in length or 100000 or more nucleotide pairs in length.
  • the target polynucleotide is usually present in any suitable sample.
  • the present application embodiment is usually implemented on a sample known to contain or suspected to contain the target polynucleotide.
  • the present application embodiment can be implemented to a sample to confirm the identity of one or more target polynucleotides known or expected to be present in the sample.
  • the sample can be a biological sample.
  • the present application embodiment can be implemented in vitro for samples obtained or extracted from any organism or microorganism.
  • the organism or microorganism is usually ancient nuclear, prokaryotic or eukaryotic, and usually belongs to one of the following five kingdoms: plant kingdom, animal kingdom, fungi, ankaryotic protozoa and protists.
  • the present application embodiment is implemented in vitro for samples obtained or extracted from any virus.
  • the sample is preferably a liquid sample.
  • the sample usually includes the patient's body fluid.
  • the sample can be urine, lymph, saliva, mucus or amniotic fluid, but preferably blood, plasma or serum.
  • the sample is derived from humans, but can alternatively be from other mammals, such as from commercially raised animals such as horses, cattle, sheep or pigs, or can be pets such as cats or dogs.
  • samples of plant origin are usually obtained from commercial crops, such as cereals, beans, fruits or vegetables, such as wheat, barley, oats, Brassica, corn, soybeans, rice, bananas, apples, tomatoes, potatoes, grapes, tobacco, beans, lentils, sugarcane, cocoa, cotton.
  • the sample may be a non-biological sample.
  • the non-biological sample is preferably a liquid sample.
  • Examples of non-biological samples include surgical fluids, water such as drinking water, sea water or river water, and reagents for laboratory tests.
  • the sample is usually processed before being used in the present application embodiment, for example, by centrifugation or filtering through a membrane to remove unwanted molecules or cells, such as red blood cells.
  • the test can be performed immediately after obtaining the sample.
  • the sample can also be stored before analysis, preferably below -70°C.
  • a pore is a structure that spans the membrane to some extent. It allows hydrated ions to flow across or within the membrane by driving them through an applied potential. A pore usually spans the entire membrane to allow hydrated ions to flow through the membrane.
  • the pores may be formed by a membrane having a plurality of pores, each of which is a well in the membrane, along which hydrated ions may flow or flow.
  • Suitable pores include, but are not limited to, protein pores, polynucleotide pores, and solid-state pores.
  • Suitable membranes are preferably amphiphilic layers.
  • An amphiphilic layer is a layer formed by amphiphilic molecules, such as phospholipids, which have hydrophilicity and lipophilicity. Amphiphilic molecules can be synthetic or naturally occurring.
  • An amphiphilic layer can be a monolayer or a bilayer.
  • An amphiphilic layer is typically planar.
  • An amphiphilic layer can be curved.
  • the amphiphilic layer can be supported.
  • the membrane can be a lipid bilayer.
  • a lipid bilayer is formed by two opposing layers of lipids. The two layers of lipids are arranged so that their hydrophobic tail groups face each other to form a hydrophobic interior.
  • the hydrophilic head groups of the lipids face outward toward the aqueous environment on each side of the bilayer.
  • the membrane includes a solid layer.
  • the solid layer can be formed by organic and inorganic materials. If the membrane includes a solid layer, holes are typically present in the amphiphilic membrane or in a layer included in the solid layer, such as holes, wells, gaps, channels, grooves or slits in the solid layer.
  • the polynucleotide may be attached to the membrane. This may be accomplished using any known method. If the membrane is an amphiphilic layer, such as a lipid bilayer, the polynucleotide is preferably attached to the membrane via a polypeptide present in the membrane or via a hydrophobic anchor present in the membrane.
  • the hydrophobic anchor is preferably a lipid, a fatty acid, a sterol, a carbon nanotube or an amino acid.
  • the polynucleotide can be directly connected to the membrane.
  • the polynucleotide is preferably connected to the membrane through a connector.
  • Preferred connectors include, but are not limited to, polymers, such as polynucleotides, polyethylene glycol (PEG) and polypeptides. If the polynucleotide is directly connected to the membrane, due to the distance between the membrane and the helicase, the characterization cannot be carried out to the end of the polynucleotide, and some data will be lost. If a connector is used, the polynucleotide can be fully characterized. If a connector is used, the connector can be connected to any position of the polynucleotide. The connector is usually connected to the tail polymer of the polynucleotide.
  • connection can be stable or temporary. For some applications, the temporary nature of the connection is preferred. If the stable linker is directly connected to the 5' end or 3' end of the polynucleotide, then due to the distance between the active site of the membrane and the helicase, the characterization can not proceed to the end of the polynucleotide, which will cause the loss of data. If the connection is temporary, then when the end of the connection randomly becomes without membrane, the polynucleotide can be characterized completely. In a preferred embodiment, the polynucleotide is connected to an amphiphilic layer.
  • Transmembrane pores or nanopores are preferably transmembrane protein pores, which define channels or holes that allow molecules and ions to be translocated from one side of the membrane to the other side.
  • the translocation of ionic substances through the hole can be driven by a potential difference applied to either side of the hole.”
  • Nanopore is a protein pore or transmembrane pore, in which the minimum diameter of the channel through which molecules or ions pass is nanometer-scale ( 10-9 meters).
  • the protein pore can be a transmembrane protein pore or a transmembrane pore or a nanopore.
  • the transmembrane protein structure of the transmembrane pore can be a monomer or an oligomer in nature.
  • the hole comprises a plurality of polypeptide subunits arranged around a central axis, thereby forming a protein-lined channel extending substantially perpendicular to the membrane where the hole resides.
  • the number of polypeptide subunits is not limited. Typically, the number of subunits is 5 to 30, and the number of subunits is suitably 6 to 10. Alternatively, the number of subunits is not defined as in the case of perfringolysin or related large membrane pores.
  • the portion of the protein subunit that forms the protein-lined channel within the pore typically comprises secondary structural motifs that may include one or more transmembrane ⁇ -barrels and/or ⁇ -helical portions.
  • the method of the embodiment can measure two, three, four or five or more characteristics of the polynucleotide.
  • the one or more characteristics are preferably selected from (i) the length of the polynucleotide, (ii) the identity of the polynucleotide, (iii) the sequence of the polynucleotide, (iv) the secondary structure of the polynucleotide, and (v) whether the polynucleotide is modified. In one embodiment, any combination of (i) to (v) can be measured.
  • the length of the polynucleotide may be measured, for example, by determining the number of interactions between the polynucleotide and the pore or the duration of interactions between the polynucleotide and the pore.
  • the identity of a polynucleotide can be measured in a variety of ways, and the identity of a polynucleotide can be measured in conjunction with or without measurement of the polynucleotide sequence.
  • the former is relatively simple; the polynucleotide is sequenced and identified.
  • the latter can be accomplished in several different ways. For example, the presence of a particular motif in a polynucleotide can be measured (without measuring the rest of the sequence of the polynucleotide).
  • the measurement of a specific electrical and/or optical signal in the method can identify that the polynucleotide is from a particular source.
  • sequence of the polynucleotide can be determined as previously described.
  • secondary structure can be measured using a variety of methods. For example, if the method involves an electrical measurement method, the secondary structure can be measured using a change in residence time or a change in the current flowing through the pore. This allows for the differentiation of regions of single-stranded and double-stranded polynucleotides.
  • the presence or absence of any modification may be measured.
  • the method preferably comprises determining whether the polynucleotide is modified by methylation, oxidation, damage, treatment with one or more proteins or with one or more markers, tags or is abasic or lacking nucleobases and sugars.
  • the decoration will result in a specific interaction with the pore, which can be measured using the methods described below.
  • methylcytosine can be distinguished from cytosine based on the current flowing through the pore during its interaction with each nucleotide.
  • Electrical measurements include voltage measurements, capacitance measurements, current measurements, impedance measurements, tunneling measurements (Ivanov AP et al., Nano Lett. 2011 Jan 12; 11(I): 279-85) and FET measurements (International Application WO 2005/124888).
  • Optical measurements can be combined with electrical measurements (Soni GV et al., Rev Sci Instrum. 2010 Jan; 81(1) 014301).
  • the measurement can be a transmembrane current measurement, such as a measurement of the ionic current flowing through the pore.
  • the electrical measurement or optical measurement can use conventional electrical or optical measurements.
  • Electrical measurements can be made using standard single channel recording equipment as described in Stoddart D et al., Proc Natl Acad Sci, 12; 106 (19) 7702-7, Lieberman KR et al., J Am Chem Soc. 2010; 132 (50) 17961-72 and international application WO 2000/28312.
  • electrical measurements can be made using a multi-channel system, such as described in international application WO 2009/077734 and international application WO 2011/067559.
  • the method is preferably performed using an applied potential across the membrane.
  • the applied potential may be a voltage potential.
  • the applied potential may be a chemical potential.
  • An example of this is the use of a salt gradient across a membrane, such as a layer of amphiphilic molecules. Salt gradients are disclosed in Holden et al., J Am Chem SOC. 2007 Jul 11; 129(27): 8650-5.
  • the current flowing through the pore as the polynucleotide moves relative to the pore is used to estimate or determine the sequence of the polynucleotide. This is strand sequencing.
  • the method may include measuring the current flowing through the hole when the polynucleotide moves relative to the hole. Therefore, the equipment used for the method may also include a circuit capable of applying an electric potential and measuring the electrical signal passing through the membrane and the hole. The method may be performed using a patch clamp or a voltage clamp.
  • the method is usually carried out by applying a voltage to the membrane and the hole.
  • the voltage used is usually from +5V to -5V, for example from +4V to -4V, from +3V to -3V or from +2V to -2V.
  • the voltage used is usually from -600mV to +600V or -400mV to +400mV.
  • the voltage used is preferably selected from -400mV, -300mV, -200mV, -150mV, -100mV, -50mV, -20mV and 0mV lower limit and independently selected from +10mV,
  • the voltage used is more preferably in the range of 100mV to 240mV and most preferably in the range of 120mV to 220mV.
  • the method is generally carried out in the presence of any charge carrier, such as a metal salt such as an alkali metal salt, a halide salt such as a chloride salt, such as an alkali metal chloride salt.
  • the charge carrier may include an ionic liquid or an organic salt, such as tetramethylammonium chloride, trimethylphenylammonium chloride, phenyltrimethylammonium chloride or 1-ethyl-3-methylimidazolium chloride.
  • the salt is present in an aqueous solution in the chamber.
  • Potassium chloride (KCl), sodium chloride (NaCl), cesium chloride (CsCl) or a mixture of potassium ferrocyanide and potassium ferrocyanide are generally used.
  • KCl, NaCl and a mixture of potassium ferrocyanide and potassium ferrocyanide are preferred.
  • the charge carrier may be asymmetric on the membrane. For example, the type and/or concentration of the charge carrier may be different on each side of the membrane
  • the concentration of the salt may be saturated.
  • the concentration of the salt may be 3 M or less, and is typically 0.1 to 2.5 M, 0.3 to 1.9 M, 0.5 to 1.8 M, 0.7 to 1.7 M, 0.9 to 1.6 M or 1 M to 1.4 M.
  • the concentration of the salt is preferably 150 mM to 1 M.
  • the method is preferably performed using a salt concentration of at least 0.3 M, such as at least 0.4 M, at least 0.5 M, at least 0.6 M, at least 0.8 M, at least 1.0 M, at least 1.5 M, at least 2.0 M, at least 2.5 M or at least 3.0 M.
  • High salt concentrations provide a high signal-to-noise ratio and allow the presence of nucleotides to be identified in the context of normal current fluctuations to be indicated by current.
  • the method is usually carried out in the presence of a buffer.
  • the buffer is present in an aqueous solution in the chamber. Any buffer can be used in the method of the present application embodiment.
  • the buffer is a phosphate buffer.
  • Other suitable buffers are HEPES or Tris-HCl buffer.
  • the method is usually carried out at a pH of 4.0 to 12.0, 4.5 to 10.0, 5.0 to 9.0, 5.5 to 8.8, 6.0 to 8.7, 7.0 to 8.8 or 7.5 to 8.5.
  • the pH used is preferably about 7.5.
  • the method can be carried out at a temperature of 0°C to 100°C, 15°C to 95°C, 16°C to 90°C, 17°C to 85°C, 18°C to 80°C, 19°C to 70°C or 20°C to 60°C.
  • the method is typically carried out at room temperature.
  • the method is optionally carried out at a temperature that supports enzyme function, such as about 37°C.
  • the method includes:
  • the target analyte preferably the target polynucleotide
  • the solution of the embodiment of the present application contacting the pore with a helicase or a construct of an embodiment of the present application such that the target analyte, preferably a target polynucleotide, moves through the pore and the helicase or construct controls the movement of the target analyte, preferably a target polynucleotide, through the pore;
  • the method can be implemented using any device suitable for studying membrane/pore systems (wherein the pores are embedded in the membrane).
  • the method can be implemented using a device suitable for sensing the pores.
  • the device comprises a chamber comprising an aqueous solution and a barrier that divides the chamber into two parts.
  • the barrier typically has a gap in which a membrane comprising the pores is formed.
  • the barrier forms a membrane in which the pores are present.
  • the method can be implemented using the device described in International Application No. PCT/GB08/000562 (WO 2008/102120).
  • the method may include measuring the current through the hole as the target analyte, preferably the polynucleotide, moves relative to the hole. Therefore, the device may also include a circuit capable of applying a potential across the membrane and the hole and measuring the current signal.
  • the method may be implemented using a patch clamp or a voltage clamp.
  • the method preferably comprises the use of a voltage clamp.
  • the target polynucleotide may be contacted with a helicase or construct and the hole in any order.
  • the target analyte preferably the target polynucleotide
  • the target analyte preferably the target polynucleotide, first forms a complex with the helicase or construct.
  • the target analyte preferably the target polynucleotide/helicase or construct complex then forms a complex with the hole and controls the target analyte, preferably the polynucleotide, to move through the hole.
  • the present application embodiment also provides the sensor and method thereof formed for characterizing the preferred target polynucleotide of target analyte.Described method is included in the helicase of hole and embodiment, preferably Dda helicase, more preferably forms complex between the construct of T4-Dda helicase, enzyme or the present application embodiment.
  • helicase can be any helicase described above for the construct of the present application embodiment, comprises the helicase of the present application embodiment and the helicase not modified according to the present application embodiment.
  • the Dda helicase of the present application embodiment discussed for the group and method of the present application embodiment of any number and combination can be used.
  • the complex can be formed by contacting the pore and the helicase or construct in the presence of a target analyte, preferably a target polynucleotide, and then applying an electric potential to the pore.
  • the applied electric potential can be a chemical potential or a voltage potential as described above.
  • the complex can be formed by The via hole is covalently connected to the helicase or construct to form.
  • the method of covalent connection is known in the art and, for example, disclosed in International Application No. PCT/GB09/001679 (publication number is WO 2010/004265) and PCT/GB10/000133 (publication number is WO 2010/086603).
  • the complex is a sensor for characterizing a target analyte, preferably a target polynucleotide.
  • the method preferably includes forming a complex between a hole derived from Msp and a helicase of the present application embodiment or a construct of the present application embodiment. Any embodiment of the present application embodiment method discussed above is equally applicable to the method.
  • the present application embodiment also provides a sensor prepared using the method of the present application embodiment.
  • the present application embodiment also provides a test kit for characterizing the preferred target polynucleotide of target analyte.
  • the test kit includes the helicase of (a) hole and (b) embodiment, preferably Dda helicase, more preferably T4-Dda helicase, or the construct of the present application embodiment. Any embodiment discussed above for the present application embodiment method is equally applicable to the test kit.
  • the helicase can be any helicase described for the construct of the present application embodiment above, including the helicase of the present application embodiment and the helicase not modified according to the present application embodiment.
  • the test kit can include the helicase of the present application embodiment discussed for the group and method of the present application embodiment using any number and combination, preferably Dda helicase, more preferably T4-Dda helicase.
  • the kit may further include components of the membrane, such as phospholipids required to form an amphiphilic layer such as a lipid bilayer.
  • the kit of the present application embodiment may additionally include one or more other reagents or instruments that enable any of the embodiments described above to be implemented.
  • the reagents or instruments include one or more of the following: a suitable buffer (aqueous solution), an instrument for obtaining a sample from a receptor (such as a catheter or an instrument containing a needle), an instrument for amplifying and/or expressing polynucleotides, a membrane as defined above or a voltage clamp or patch clamp device.
  • the reagent present in the kit may be dry so that the liquid sample resuspends the reagent.
  • the kit may also optionally include an instrument that enables the kit to be used in the present application embodiment method or instructions for which patients the method may be used for.
  • the kit may optionally include nucleotides.
  • the present application also provides a device for characterizing a target analyte, preferably a target polynucleotide.
  • the device comprises a plurality of holes and a plurality of helicases, preferably a Dda helicase, more preferably a T4-Dda helicase, a plurality of helicases of the present application or a plurality of constructs of the present application. Construct.
  • the device preferably further includes instructions for implementing the method of the embodiment of the present application.
  • the device can be any conventional device for target analyte, preferably polynucleotide analysis, such as an array or a chip. Any embodiment of the method of the embodiment of the present application discussed above can be equally applicable to the device of the embodiment of the present application.
  • the helicase can be any helicase described above for the construct of the embodiment of the present application, including the helicase of the embodiment of the present application and the helicase that is not modified according to the embodiment of the present application.
  • the device may include the helicase of the embodiment of the present application discussed above for the group and method of the embodiment of the present application using any number and combination, preferably Dda helicase, more preferably T4-Dda helicase.
  • the device is preferably assembled to implement the method of the embodiment of the present application.
  • the device preferably comprises:
  • a sensor device capable of supporting a plurality of pores and operable to use the pores and the helicase or construct to characterize a target analyte, preferably a polynucleotide;
  • the device preferably comprises:
  • a sensor device capable of supporting a plurality of pores and operable to use the pores and the helicase or construct to characterize a target analyte, preferably a polynucleotide;
  • At least one memory for storing materials for characterization.
  • the device more preferably comprises:
  • a sensor device capable of supporting the membrane and the plurality of pores and operable to characterize a target analyte, preferably a polynucleotide, using the pores and the helicase or construct;
  • At least one memory storing material for characterization
  • a fluidics system configured to controllably supply material to the sensor device from at least one reservoir; and one or more containers for receiving each sample, the fluidics system being configured to selectively supply samples from the one or more containers to the sensor device.
  • the device may be any of those described in International Application No. PCT/GB08/004127 (published as WO 2009/077734), PCT/GB10/000789 (published as WO 2010/122293), International Application No. PCT/GB10/002206 (published as WO 2011/067559) or International Application No. PCT/US99/25679 (published as WO 00/28312).
  • the present application also provides a method for preparing the modified helicase of the present application.
  • the method includes providing a helicase, preferably a Dda helicase, more preferably a T4-Dda helicase to form the modified helicase of the present application.
  • the method preferably further comprises determining whether the helicase can control the movement of the target analyte, preferably a polynucleotide.
  • the analysis performed on it is described above. If the movement of the target analyte, preferably a polynucleotide, can be controlled, the helicase is correctly modified and the helicase of the present application embodiment is obtained. If the movement of the target analyte, preferably a polynucleotide, cannot be controlled, the helicase of the present application embodiment is not obtained.
  • the present application also provides a method for preparing the construct.
  • the method comprises connecting, preferably covalently connecting, a helicase of the present application, preferably a Dda helicase, more preferably a T4-Dda helicase to an adapter. Any helicase and adapter as described above can be used in the method.
  • the method preferably further comprises determining whether the construct can control the movement of the target analyte, preferably polynucleotide.
  • the analysis performed on it is described above. If the movement of the target analyte, preferably polynucleotide, can be controlled, the helicase and adapter are correctly connected, and the construct of the present application embodiment is obtained. If the movement of the target analyte, preferably polynucleotide, cannot be controlled, the construct of the present application embodiment is not obtained.
  • Example 1.1 Enzyme cross-linking mediated by different catalytic systems
  • Antisense strand S2 5'- CGACTTCTACCGTTTGACTCCGC (SEQ ID NO: 3)-3'
  • Connection chain YB (SEQ ID NO: 4)/i2OMeG//i2OMeC//i2OMeA//i2OMeG//i2OMeU//i2OMeA//i2OMeG//i2OMeU//i2OMeC//i2OMeC//i2OMeA//i2OMeG//i2OMeC//i2OMeA//i2OMeC//i2OMeC//i2OMeC//i2OMeG//i2OMeA//i2OMeC/-3' respectively synthesize the main strand S1, the antisense strand S2 and the connecting strand YB, and mix and anneal the three at a ratio of 1:1.1:1.1 to form an adapter.
  • the annealing treatment is specifically to slowly cool from 95°C to 25°C, during which the cooling amplitude does not exceed 0.1°C/s.
  • Two reaction systems were prepared, each with 1uM adapter, 5 times the amount of Q1 (mutant T4DDA-E93Q) protein, and no catalyst, 0.1U microbial transglutaminase as a catalyst, mixed and incubated at 37°C for 36h, then run TBE PAGE gel at 160V for 40min and detect the enzyme cross-linking.
  • the results are shown in Figure 2.
  • the nucleic acid protein complex is a complex of the adapter and the helicase. After adding microbial transglutaminase, an effective cross-linking product can be formed.
  • Two reaction systems were prepared, each with 1uM adapter, 5 times the amount of Q11 (mutant T4DDA-E94G) protein, and no catalyst, 5mM EDC as a catalyst, mixed and incubated at 30°C for 4h, then run TBE PAGE gel at 160V for 40min and detect the enzyme cross-linking.
  • the results are shown in Figure 3, the nucleic acid protein complex is a complex of the adapter and the helicase. After adding EDC, an effective cross-linking product can be formed.
  • Antisense strand S2 5’-Ru-CGACTTCTACCGTTTGACTCCGC (SEQ ID NO: 3)-3’
  • Connection chain YB 5’P-GTCAGCAGGACCGAATGA(SEQ ID NO:4)/i2OMeG//i2OMeC//i2OMeA//i2OMeG//i2OMeU//i2OMeA//i2OMeG//i2OM eU//i2OMeC//i2OMeA//i2OMeG//i2OMeC//i2OMeA//i2OMeC//i2OMeC//i2OMeC//i2OMeC//i2OMeG//i2OMeA//i2OMeC//i2OMeC/-3’
  • the main strand S1, antisense strand S2 and connecting strand YB are synthesized separately, and the three are mixed and annealed at a ratio of 1:1.1:1.1 to form a linker.
  • the annealing treatment is specifically to slowly cool from 95°C to 25°C, during which the cooling amplitude does not exceed 0.1°C/s.
  • reaction systems were prepared, each with 2uM adapter, 4 times the amount of T49 (mutant T4 DDA-E94Y) or 4 times the amount of T53 protein/1mM 1,4-diamine were added, mixed and placed at 30°C for incubation for 30min, then 1.25mM sodium persulfate was added and placed under LED 450nM light for crosslinking (light power of 50mw/ cm2 ; distance 15cm), then TBE PAGE gel was run at 160V for 40min and the enzyme crosslinking was detected, the results are shown in Figure 4.
  • the nucleic acid protein complex is a complex of the adapter and the helicase. Under Ru light catalysis, it can be clearly found that the enzyme has been crosslinked (Y94-K364 in T49; Y94 and N365Y in T53 are crosslinked with 1,4-diamine).
  • Example 1.4 Preparation of nucleic acid-protein complexes based on Tyr-Tyr cross-linking
  • the enzyme cross-linking product catalyzed by HRP/H 2 O 2 in Example 1.1 was added to a DNAPac PA200 column and purified using an elution buffer to remove impurities such as enzymes that were not bound to the adapter and incompletely reacted EDC from the column.
  • the nucleic acid-protein complex was eluted with a mixture of buffer A and buffer B with 10 column volumes.
  • the main elution peaks were then collected, their concentrations were measured, and TBE PAGE gel was run at 160V for 40 minutes.
  • buffer A 20mM Na-CHES, 250mM NaCl, 4% (W/V) glycerol, pH 8.6
  • buffer B 20mM Na-CHES, 1M NaCl, 4% (W/V) glycerol, pH 8.6.
  • the elution process is shown in Figure 6.
  • the peaks in the elution process were collected and detected by TBE PAGE gel running at 160V for 40 minutes.
  • the results are shown in Figure 7.
  • E3 is the desired nucleic acid-protein complex.
  • Example 1.5 On-machine testing of nucleic acid-protein complexes based on Tyr-Tyr cross-linking
  • a 10 kb library was prepared by end repair, and the nucleic acid protein complex in Example 1.4 was connected to the library. Finally, sequencing was performed on the QNome-3841 of Qi Carbon Technology Co., Ltd. The actual sequencing signal is shown in Figure 8.
  • the nucleic acid protein complex can generate sequencing signals normally, and the signal steps are clear for subsequent base inference.
  • the complete library pass-through signal can be seen. This shows that the formation of the 1A domain and the 2A domain
  • the helicase that forms the Tyr-Tyr ectopic bond between the two molecules can control the movement of the target polynucleotide and can be used for nanopore sequencing of polynucleotides.
  • Example 1.6 Analysis of sequencing accuracy based on Tyr-Tyr cross-linking
  • a randomly interrupted Human genome library was prepared by end repair, and the nucleic acid-protein complex or disulfide-crosslinked SAC-M1 (nucleic acid-protein complex formed by T4Dda-E94C/A360C) in Example 1.4 was connected to the library. Finally, sequencing was performed on the QNome-3841 of Qi Carbon Technology Co., Ltd. Under the same small data set training scale, the accuracy based on Tyr-Tyr cross-linking was higher than the traditional disulfide cross-linking form, and the analysis results are shown in Table 4.
  • Normalized noise The signal value of each read is standardized by the Median Absolute Deviation (MAD), the signal and noise are separated by median filtering, and the root mean square (RMS) value of the noise is calculated as an indicator of normalized noise.
  • MAD Median Absolute Deviation
  • RMS root mean square
  • Noise Perform median filtering on the signal value of each read to obtain the filtered noise signal. Calculate the root mean square (RMS) value of the noise signal as an indicator of noise, reflecting the relative intensity of noise. The smaller the noise value, the smaller the noise interference.
  • RMS root mean square
  • Signal-to-noise ratio The signal value of each read is normalized by the Median Absolute Deviation (MAD), and the signal and noise are separated by median filtering.
  • the signal-to-noise ratio is expressed as the ratio of signal power to noise power. The larger the signal-to-noise value, the better the signal quality and the smaller the noise interference.
  • val loss It is the error between the predicted result of the validation data set through the neural network model and the actual result.
  • ACC It is the accuracy of the prediction results of the validation data set through the neural network model compared with the actual results.
  • the main strand S1, antisense strand S2 and connecting strand YB were synthesized respectively, and their specific sequences are shown below:
  • Antisense strand S2 5’-Ru-CGACTTCTACCGTTTGACTCCGC-3’
  • Connection chain YB 5’-GTCAGCAGGACCGAATGA/i2OMeG//i2OMeC//i2OMeA//i2OMeG//i2OMeU//i2OMeA//i2OMeG//i2OMeU//i2O MeC//i2OMeC//i2OMeA//i2OMeG//i2OMeC//i2OMeC//i2OMeC//i2OMeC//i2OMeG//i2OMeA//i2OMeC//i2OMeC/-3’
  • the main strand S1 sequentially comprises the leading sequence iSpC3 (i.e., a nucleotide lacking sugar and base, indicated as 3), which is connected to the 5' end of SEQ ID NO: 1, and the 3' end of SEQ ID NO: 1 is sequentially connected to the blocking strand iSpC18 (indicated as 8888) and the 5' end of SEQ ID NO: 2.
  • iSpC3 and iSpC18 were purchased from Integrated DNA Technologies.
  • the sequence of the antisense strand S2 is shown in SEQ ID NO:3.
  • the connecting chain YB comprises the sequence shown in SEQ ID NO:4, and its 3’ end is connected to multiple methoxy modifications, including i2OMeA, i2OMeC, i2OMeG, and i2OMeU.
  • the main strand S1, the antisense strand S2 and the connecting strand YB are mixed and annealed at a ratio of 1:1.1:1.1 to form an adapter.
  • the annealing treatment is specifically to slowly cool from 95°C to 25°C, during which the cooling amplitude does not exceed 0.1°C/s.
  • Example 2.2 Preparation of nucleic acid-protein complex based on Lys-Glu linkage
  • the main strand S1, antisense strand S2 and connecting strand YB were synthesized respectively, and their specific sequences are shown below:
  • Antisense strand S2 5’-CGACTTCTACCGTTTGACTCCGC-3’
  • Connection chain YB 5’-GTCAGCAGGACCGAATGA/i2OMeG//i2OMeC//i2OMeA//i2OMeG//i2OMeU//i2OMeA//i2OMeG//i2OMeU//i2O MeC//i2OMeC//i2OMeA//i2OMeG//i2OMeC//i2OMeC//i2OMeC//i2OMeC//i2OMeG//i2OMeA//i2OMeC//i2OMeC/-3’
  • the main strand S1 sequentially comprises the leading sequence iSpC3 (i.e., a nucleotide lacking sugar and base, indicated as 3), which is connected to the 5' end of SEQ ID NO: 1, and the 3' end of SEQ ID NO: 1 is sequentially connected to the blocking strand iSpC18 (indicated as 8888) and the 5' end of SEQ ID NO: 2.
  • iSpC3 and iSpC18 were purchased from Integrated DNA Technologies.
  • the sequence of the antisense strand S2 is shown in SEQ ID NO:3.
  • the connecting chain YB comprises the sequence shown in SEQ ID NO:4, and its 3’ end is connected to multiple methoxy modifications, including i2OMeA, i2OMeC, i2OMeG, and i2OMeU.
  • the main strand S1, the antisense strand S2 and the connecting strand YB are mixed and annealed at a ratio of 1:1.1:1.1 to form an adapter.
  • the annealing treatment is specifically to slowly cool from 95°C to 25°C, during which the cooling amplitude does not exceed 0.1°C/s.
  • Example 2.2 Add 5 times the amount of substance added in Example 2.2 to the DNAPac PA200 column and purify it with buffer A and buffer B to remove impurities such as enzymes that are not bound to the linker and incompletely reacted EDC from the column.
  • the nucleic acid-protein complex was then eluted with a mixture of 10 column volumes of buffer A and buffer B.
  • the main elution peaks were then pooled, their concentrations measured, and run on a TBE PAGE gel at 160V for 40 min.
  • the composition of buffer A is: 20mM Na-CHES, 250mM NaCl, 4% (W/V) glycerol, pH 8.6;
  • the composition of buffer B is: 20mM Na-CHES, 1M NaCl, 4% (W/V) glycerol, pH 8.6.
  • the eluted main peak was quantified by Qubit, and 10 ng was taken for quality inspection.
  • Example 2.4 ATP consumption detection of nucleic acid-protein complexes
  • Example 2.3 About 1 ng of the purified nucleic acid-protein complex in Example 2.3 was taken and added to 200 ⁇ L 1*Seq Buffer (10 mM HEPES7.0, 600 mM KCl, 25 mM ATP, 25 mM MgCl 2 ), and enzyme-free water was added without adding nucleic acid-protein complex as a control. After that, 0 h, 4 h, and 8 h were taken and the ADP content was detected by HPLC according to the peak time of elution on the C18 column, and the results are shown in Figure 14. The results show that under this enzyme locking mode, the nucleic acid-protein complex still has ATPase activity and the protein can still work normally.
  • 1*Seq Buffer 10 mM HEPES7.0, 600 mM KCl, 25 mM ATP, 25 mM MgCl 2
  • enzyme-free water was added without adding nucleic acid-protein complex as a control.
  • a 10 kb library was prepared by end repair, and the nucleic acid protein complex prepared in Example 2.2 was connected to the library for library construction according to the library construction kit QLK-V1.1.1 of Qi Carbon Technology. Finally, sequencing was performed on the QNome-3841 sequencer of Qi Carbon Technology Co., Ltd., and the actual sequencing signal is shown in Figure 15. The results show that the nucleic acid protein complex can generate sequencing signals normally, and the signal steps are clear for subsequent base inference.
  • the method for preparing the nucleic acid-protein complex without forming cross-links is similar to that in Example 2.2, except that no EDC is added during the preparation process, that is, the enzyme does not form cross-links.
  • Example 5 The library construction and sequencing were performed in the same manner as in Example 2.5, and the results are shown in Table 5. The results showed that compared with Example 2.5, the enzyme in the complex of the non-cross-linked enzyme was easily detached during sequencing, and no effective sequencing signal could be obtained, let alone a complete sequencing signal of 10 kb.
  • a valid signal is a signal that can be subsequently identified by basecalling and converted into a sequence.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une hélicase, dans laquelle une liaison ectopique est formée, l'hélicase préservant la capacité de contrôler le mouvement d'un analyte cible, et la liaison ectopique ne comprenant pas de liaison ectopique où sa formation implique de la cystéine. L'invention concerne en outre un polypeptide, une construction, un polynucléotide, un vecteur et une cellule hôte ; un procédé de préparation de l'hélicase, du polypeptide ou de la construction ; un procédé de contrôle du mouvement d'un analyte cible ; un procédé de caractérisation d'un analyte cible ; un procédé de formation d'un capteur pour caractériser un analyte cible ; un capteur pour caractériser un analyte cible ; l'utilisation de l'hélicase ou de la construction pour contrôler le mouvement d'un analyte cible à travers un pore ; un kit ou un dispositif pour caractériser un analyte cible ; et un ensemble d'au moins deux hélicases se liant à un analyte cible.
PCT/CN2024/121291 2023-09-27 2024-09-26 Hélicase et utilisation associée Pending WO2025067293A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202311261708.8 2023-09-27
CN202311266570.0A CN119709690A (zh) 2023-09-27 2023-09-27 一种用于纳米孔测序的酶修饰方法
CN202311261708.8A CN119709689A (zh) 2023-09-27 2023-09-27 解旋酶及其应用
CN202311266570.0 2023-09-27

Publications (1)

Publication Number Publication Date
WO2025067293A1 true WO2025067293A1 (fr) 2025-04-03

Family

ID=95204362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2024/121291 Pending WO2025067293A1 (fr) 2023-09-27 2024-09-26 Hélicase et utilisation associée

Country Status (1)

Country Link
WO (1) WO2025067293A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899678A (zh) * 2013-10-18 2016-08-24 牛津纳米孔技术公司 经修饰的酶
CN107109483A (zh) * 2014-10-14 2017-08-29 牛津纳米孔技术公司 方法
CN107109380A (zh) * 2014-10-07 2017-08-29 牛津纳米孔技术公司 经修饰的酶
WO2021253410A1 (fr) * 2020-06-19 2021-12-23 北京齐碳科技有限公司 Hélicase de type pif1 et utilisation associée
WO2022213253A1 (fr) * 2021-04-06 2022-10-13 成都齐碳科技有限公司 Prp43 hélicase modifiée et son utilisation
CN116497102A (zh) * 2021-12-21 2023-07-28 成都齐碳科技有限公司 用于表征目标多核苷酸的衔接体、方法及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899678A (zh) * 2013-10-18 2016-08-24 牛津纳米孔技术公司 经修饰的酶
CN107109380A (zh) * 2014-10-07 2017-08-29 牛津纳米孔技术公司 经修饰的酶
CN107109483A (zh) * 2014-10-14 2017-08-29 牛津纳米孔技术公司 方法
WO2021253410A1 (fr) * 2020-06-19 2021-12-23 北京齐碳科技有限公司 Hélicase de type pif1 et utilisation associée
WO2022213253A1 (fr) * 2021-04-06 2022-10-13 成都齐碳科技有限公司 Prp43 hélicase modifiée et son utilisation
CN116497102A (zh) * 2021-12-21 2023-07-28 成都齐碳科技有限公司 用于表征目标多核苷酸的衔接体、方法及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN 28 April 1993 (1993-04-28), "DNA helicase, partial [Escherichia phage T4]", XP093297050, Database accession no. AAA32488.1 *
HE, XIAOPING ET AL.: "The T4 Phage SF1B Helicase Dda is Structurally Optimized to Perform DNA Strand Separation", STRUCTURE, vol. 20, 3 July 2012 (2012-07-03), pages 1189 - 1200, XP028399006, DOI: 10.1016/j.str.2012.04.013 *
WANUNU MENI: "Back and forth with nanopore peptide sequencing", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 40, no. 2, 20 January 2022 (2022-01-20), New York, pages 172 - 173, XP037691462, ISSN: 1087-0156, DOI: 10.1038/s41587-021-01205-x *

Similar Documents

Publication Publication Date Title
US20230374583A1 (en) Method of target molecule characterisation using a molecular pore
US11560589B2 (en) Enzyme stalling method
CN104126018B (zh) 酶方法
EP3619224B1 (fr) Pore transmembranaire constitué de deux pores csgg
CN106460061B (zh) 在双链核酸分子的两端使用纳米孔和锚分子来表征所述双链核酸的方法
EP3440098B1 (fr) Pore mutant
EP2836506B1 (fr) Pores de mutants de lysenin
EP3207157B1 (fr) Procede permettant le transfert d'un analyte au nanopore
EP3259281B1 (fr) Hétéro-pores
CN113912683B (zh) 孔蛋白单体的突变体、蛋白孔及其应用
CN113773373B (zh) 孔蛋白单体的突变体、蛋白孔及其应用
CN116601297A (zh) 一种经修饰的解旋酶及其应用
CN114854826A (zh) 序列、包含序列的接头及其用途
US20240240248A1 (en) Methods for complement strand sequencing
WO2025067293A1 (fr) Hélicase et utilisation associée
CN119709689A (zh) 解旋酶及其应用
EP4362028A1 (fr) Aérolysine mutante et ses utilisations
CN119753110A (zh) 用于表征被分析物的衔接体、表征方法及其应用
HK40075988A (en) Sequences, linkers comprising sequences and uses thereof
WO2023060422A1 (fr) Mutant de monomère de porine, pore protéique et leur utilisation
WO2023060419A1 (fr) Mutant de monomère de porine, pore protéique et leur application
WO2023060420A1 (fr) Mutant de monomère de porine, pore protéique et leur utilisation
WO2023060421A1 (fr) Mutant de monomère de porine, pore protéique et utilisation associée
WO2023050031A1 (fr) Mutant de monomère de porine, pore protéique et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24870837

Country of ref document: EP

Kind code of ref document: A1